Mortality at 1 year for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularization : do tirofiban and ReoPro give similar efficacy outcomes at trial 1-year follow-up
- Author
- MUKHERJEE, Debabrata1 ; TOPOL, Eric J2 ; ARDISSINO, Diego10 ; MOLITERNO, David J1 ; BERTRAND, Michel E3 ; KRISTENSEN, Steen D4 ; HERRMANN, Howard C5 ; NEUMANN, Franz-Josef6 ; YAKUBOV, Steven J7 ; BASSAND, Jean-Pierre8 ; MCCLURE, Rick R1 ; STONE, Gregg W9
[1] Division of Cardiovascular Medicine, Gill Heart Institute, University of Kentucky, 900 S Limestone, 326 Wethington Building, Lexington, KY 40536-0200, United States
[2] Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, OH, United States
[3] Hôpital Cardiologique, Lille, France
[4] Skejby Hospital, Aarhus University Hospital, Brendstrupgaardsvej, Denmark
[5] University of Pennsylvania Medical Center, Philadelphia, PA, United States
[6] Herz-Zentrum Bad Krozingen, Bad Krozingen, Germany
[7] Riverside Methodist Hospital, Columbus, OH, United States
[8] Jean-Minjoz Hospital, Besançon, France
[9] Columbia University Medical Center, New York, NY, United States
[10] Università Degli Studi di Parma, Parma, Italy
TARGET Investigators - Source
European heart journal. 2005, Vol 26, Num 23, pp 2524-2528, 5 p ; ref : 20 ref
- ISSN
- 0195-668X
- Scientific domain
- Cardiology, blood circulation, phlebology
- Publisher
- Oxford University Press, Oxford
- Publication country
- United Kingdom
- Document type
- Article
- Language
- English
- Author keyword
- Abciximab Glycoprotein IIb/IIIa inhibitor Mortality Percutaneous coronary intervention Tirofiban
- Keyword (fr)
- Abciximab Angioplastie Appareil circulatoire Artère coronaire Cardiologie Efficacité Epidémiologie Etude comparative Etude longitudinale Evolution Fibrinolytique Glycoprotéine IIIa Glycoprotéine IIb Mortalité Pronostic Tirofiban Traitement instrumental Voie percutanée
- Keyword (en)
- Abciximab Angioplasty Circulatory system Coronary artery Cardiology Efficiency Epidemiology Comparative study Follow up study Evolution Fibrinolytic Glycoprotein IIIa Glycoprotein IIb Mortality Prognosis Tirofiban Instrumentation therapy Percutaneous route
- Keyword (es)
- Abciximab Angioplastia Aparato circulatorio Arteria coronaria Cardiología Eficacia Epidemiología Estudio comparativo Estudio longitudinal Evolución Fibrinolítico Glicoproteína IIIa Glicoproteína IIa Mortalidad Pronóstico Tirofibán Tratamiento instrumental Vía percutánea
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B12 Cardiology. Vascular system
- Discipline
- Cardiology. Circulatory system
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 17290146
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1093/eurheartj/ehi459 
https://dx.doi.org/10.1093/eurheartj/ehi459
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:24:\"10.1093\/eurheartj\/ehi459\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:202:\"Mortality at 1 year for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularization : do tirofiban and ReoPro give similar efficacy outcomes at trial 1-year follow-up\";s:9:\"\u0000*\u0000jtitle\";s:22:\"European heart journal\";s:9:\"\u0000*\u0000stitle\";s:12:\"Eur. heart j\";s:7:\"\u0000*\u0000date\";s:4:\"2005\";s:9:\"\u0000*\u0000volume\";s:2:\"26\";s:8:\"\u0000*\u0000issue\";s:2:\"23\";s:8:\"\u0000*\u0000spage\";s:4:\"2524\";s:8:\"\u0000*\u0000epage\";s:4:\"2528\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0195-668X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"MUKHERJEE\";s:10:\"\u0000*\u0000aufirst\";s:9:\"Debabrata\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:11:{i:0;s:13:\"TOPOL, Eric J\";i:1;s:16:\"ARDISSINO, Diego\";i:2;s:18:\"MOLITERNO, David J\";i:3;s:18:\"BERTRAND, Michel E\";i:4;s:19:\"KRISTENSEN, Steen D\";i:5;s:18:\"HERRMANN, Howard C\";i:6;s:20:\"NEUMANN, Franz-Josef\";i:7;s:17:\"YAKUBOV, Steven J\";i:8;s:20:\"BASSAND, Jean-Pierre\";i:9;s:15:\"MCCLURE, Rick R\";i:10;s:14:\"STONE, Gregg W\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:202:\"Mortality at 1 year for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularization : do tirofiban and ReoPro give similar efficacy outcomes at trial 1-year follow-up\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:23:\"Oxford University Press\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"5\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:24:\"10.1093\/eurheartj\/ehi459\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:202:\"Mortality at 1 year for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularization : do tirofiban and ReoPro give similar efficacy outcomes at trial 1-year follow-up\";s:9:\"\u0000*\u0000jtitle\";s:22:\"European heart journal\";s:9:\"\u0000*\u0000stitle\";s:12:\"Eur. heart j\";s:7:\"\u0000*\u0000date\";s:4:\"2005\";s:9:\"\u0000*\u0000volume\";s:2:\"26\";s:8:\"\u0000*\u0000issue\";s:2:\"23\";s:8:\"\u0000*\u0000spage\";s:4:\"2524\";s:8:\"\u0000*\u0000epage\";s:4:\"2528\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0195-668X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"MUKHERJEE\";s:10:\"\u0000*\u0000aufirst\";s:9:\"Debabrata\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:11:{i:0;s:13:\"TOPOL, Eric J\";i:1;s:16:\"ARDISSINO, Diego\";i:2;s:18:\"MOLITERNO, David J\";i:3;s:18:\"BERTRAND, Michel E\";i:4;s:19:\"KRISTENSEN, Steen D\";i:5;s:18:\"HERRMANN, Howard C\";i:6;s:20:\"NEUMANN, Franz-Josef\";i:7;s:17:\"YAKUBOV, Steven J\";i:8;s:20:\"BASSAND, Jean-Pierre\";i:9;s:15:\"MCCLURE, Rick R\";i:10;s:14:\"STONE, Gregg W\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:202:\"Mortality at 1 year for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularization : do tirofiban and ReoPro give similar efficacy outcomes at trial 1-year follow-up\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:23:\"Oxford University Press\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"5\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:24:\"10.1093\/eurheartj\/ehi459\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:24:\"10.1093\/eurheartj\/ehi459\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:202:\"Mortality at 1 year for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularization : do tirofiban and ReoPro give similar efficacy outcomes at trial 1-year follow-up\";s:9:\"\u0000*\u0000jtitle\";s:22:\"European heart journal\";s:9:\"\u0000*\u0000stitle\";s:12:\"Eur. heart j\";s:7:\"\u0000*\u0000date\";s:4:\"2005\";s:9:\"\u0000*\u0000volume\";s:2:\"26\";s:8:\"\u0000*\u0000issue\";s:2:\"23\";s:8:\"\u0000*\u0000spage\";s:4:\"2524\";s:8:\"\u0000*\u0000epage\";s:4:\"2528\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0195-668X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"MUKHERJEE\";s:10:\"\u0000*\u0000aufirst\";s:9:\"Debabrata\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:11:{i:0;s:13:\"TOPOL, Eric J\";i:1;s:16:\"ARDISSINO, Diego\";i:2;s:18:\"MOLITERNO, David J\";i:3;s:18:\"BERTRAND, Michel E\";i:4;s:19:\"KRISTENSEN, Steen D\";i:5;s:18:\"HERRMANN, Howard C\";i:6;s:20:\"NEUMANN, Franz-Josef\";i:7;s:17:\"YAKUBOV, Steven J\";i:8;s:20:\"BASSAND, Jean-Pierre\";i:9;s:15:\"MCCLURE, Rick R\";i:10;s:14:\"STONE, Gregg W\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:202:\"Mortality at 1 year for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularization : do tirofiban and ReoPro give similar efficacy outcomes at trial 1-year follow-up\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:23:\"Oxford University Press\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"5\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:24:\"10.1093\/eurheartj\/ehi459\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:202:\"Mortality at 1 year for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularization : do tirofiban and ReoPro give similar efficacy outcomes at trial 1-year follow-up\";s:9:\"\u0000*\u0000jtitle\";s:22:\"European heart journal\";s:9:\"\u0000*\u0000stitle\";s:12:\"Eur. heart j\";s:7:\"\u0000*\u0000date\";s:4:\"2005\";s:9:\"\u0000*\u0000volume\";s:2:\"26\";s:8:\"\u0000*\u0000issue\";s:2:\"23\";s:8:\"\u0000*\u0000spage\";s:4:\"2524\";s:8:\"\u0000*\u0000epage\";s:4:\"2528\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0195-668X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"MUKHERJEE\";s:10:\"\u0000*\u0000aufirst\";s:9:\"Debabrata\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:11:{i:0;s:13:\"TOPOL, Eric J\";i:1;s:16:\"ARDISSINO, Diego\";i:2;s:18:\"MOLITERNO, David J\";i:3;s:18:\"BERTRAND, Michel E\";i:4;s:19:\"KRISTENSEN, Steen D\";i:5;s:18:\"HERRMANN, Howard C\";i:6;s:20:\"NEUMANN, Franz-Josef\";i:7;s:17:\"YAKUBOV, Steven J\";i:8;s:20:\"BASSAND, Jean-Pierre\";i:9;s:15:\"MCCLURE, Rick R\";i:10;s:14:\"STONE, Gregg W\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:202:\"Mortality at 1 year for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularization : do tirofiban and ReoPro give similar efficacy outcomes at trial 1-year follow-up\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:23:\"Oxford University Press\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"5\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:24:\"10.1093\/eurheartj\/ehi459\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:202:\"Mortality at 1 year for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularization : do tirofiban and ReoPro give similar efficacy outcomes at trial 1-year follow-up\";s:9:\"\u0000*\u0000jtitle\";s:22:\"European heart journal\";s:9:\"\u0000*\u0000stitle\";s:12:\"Eur. heart j\";s:7:\"\u0000*\u0000date\";s:4:\"2005\";s:9:\"\u0000*\u0000volume\";s:2:\"26\";s:8:\"\u0000*\u0000issue\";s:2:\"23\";s:8:\"\u0000*\u0000spage\";s:4:\"2524\";s:8:\"\u0000*\u0000epage\";s:4:\"2528\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0195-668X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"MUKHERJEE\";s:10:\"\u0000*\u0000aufirst\";s:9:\"Debabrata\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:11:{i:0;s:13:\"TOPOL, Eric J\";i:1;s:16:\"ARDISSINO, Diego\";i:2;s:18:\"MOLITERNO, David J\";i:3;s:18:\"BERTRAND, Michel E\";i:4;s:19:\"KRISTENSEN, Steen D\";i:5;s:18:\"HERRMANN, Howard C\";i:6;s:20:\"NEUMANN, Franz-Josef\";i:7;s:17:\"YAKUBOV, Steven J\";i:8;s:20:\"BASSAND, Jean-Pierre\";i:9;s:15:\"MCCLURE, Rick R\";i:10;s:14:\"STONE, Gregg W\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:202:\"Mortality at 1 year for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularization : do tirofiban and ReoPro give similar efficacy outcomes at trial 1-year follow-up\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:23:\"Oxford University Press\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"5\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
